Patients with lung cancer and paraneoplastic Hu syndrome harbor HuD-specific type 2 CD8+ T cells.

TitlePatients with lung cancer and paraneoplastic Hu syndrome harbor HuD-specific type 2 CD8+ T cells.
Publication TypeJournal Article
Year of Publication2009
AuthorsRoberts WK, Deluca IJ, Thomas A, Fak J, Williams T, Buckley N, Dousmanis AG, Posner JB, Darnell RB
JournalJ Clin Invest
Volume119
Issue7
Pagination2042-51
Date Published2009 Jul
ISSN1558-8238
KeywordsAged, CD8-Positive T-Lymphocytes, Cell Line, Tumor, ELAV Proteins, ELAV-Like Protein 4, Epitopes, Female, Gene Expression Profiling, Humans, Interferon-gamma, Interleukin-13, Lung Neoplasms, Male, Middle Aged, Paraneoplastic Cerebellar Degeneration
Abstract

Paraneoplastic neurologic disorders (PNDs) offer an uncommon opportunity to study human tumor immunity and autoimmunity. In small cell lung cancer (SCLC), expression of the HuD neuronal antigen is thought to lead to immune recognition, suppression of tumor growth, and, in a subset of patients, triggering of the Hu paraneoplastic neurologic syndrome. Antigen-specific CTLs believed to contribute to disease pathophysiology were described 10 years ago in paraneoplastic cerebellar degeneration. Despite parallel efforts, similar cells have not been defined in Hu patients. Here, we have identified HuD-specific T cells in Hu patients and provided an explanation for why their detection has been elusive. Different Hu patients harbored 1 of 2 kinds of HuD-specific CD8+ T cells: classical IFN-gamma-producing CTLs or unusual T cells that produced type 2 cytokines, most prominently IL-13 and IL-5, and lacked cytolytic activity. Further, we found evidence that SCLC tumor cells produced type 2 cytokines and that these cytokines trigger naive CD8+ T cells to adopt the atypical type 2 phenotype. These observations demonstrate the presence of an unusual noncytotoxic CD8+ T cell in patients with the Hu paraneoplastic syndrome and suggest that SCLC may evade tumor immune surveillance by skewing tumor antigen-specific T cells to this unusual noncytolytic phenotype.

DOI10.1172/JCI36131
Alternate JournalJ. Clin. Invest.
PubMed ID19509467
PubMed Central IDPMC2701858
Grant ListR01 CA085784 / CA / NCI NIH HHS / United States
UL1 RR024143 / RR / NCRR NIH HHS / United States
R01 CA85784 / CA / NCI NIH HHS / United States
/ / Howard Hughes Medical Institute / United States

Person Type: